Delayed radiotherapy for low-grade oligodendrogliomas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the timing of radiotherapy in patients with low-grade oligodendrogliomas who have not undergone prior chemotherapy or radiotherapy. The study hypothesizes that delaying radiotherapy until tumor progression may reduce the risk of neurocognitive deterioration while maintaining overall survival rates. Participants will receive PCV chemotherapy, and their outcomes will be compared based on the timing of radiotherapy. The trial aims to provide insights into optimizing treatment strategies for this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Tumor is co-deleted for 1p and 19q based and IDH-mutant (IDH1 or IDH2) according to local diagnosis
* Histological confirmation of low-grade oligodendroglioma by central pathological review according to WHO 2016 classification
* Age ≥ 18 years
* Patients with one or several prior surgical procedure for a low-grade oligodendroglioma and who undergo a resurgery are eligible if they have not received prior radiotheray or chemotherapy and if the last histological diagnosis is a low-grade oligodendroglioma prior use of specific HDI prohibitions is permitted
* Patients who undergo an initial follow-up after surgery or re-surgery are eligible if there is no evidence of anaplastic transformation on MRI (no new contrast enhancement, no obvious modification of the growth rate)
* Patients requiring an oncological treatment other than surgery because of one or more of the following characteristics:

  * Progressive disease defined as documented growth prior to inclusion
  * Symptomatic disease defined as the presence of neurological or cognitive symptoms or refractory seizures defined as having both persistent seizures interfering with everyday life activities other than driving a car and three lines of anti-epileptic drug regimen had not worked, including at least one combination regimen.
  * Age ≥ 40 and any surgical therapy
  * Age \< 40 with prior and subtotal resection or biopsy (i.e., anything less than gross total resection)
* Willing and able to complete neurocognitive examination and the QOL
* Karnofsky performance status ≥ 60
* Laboratory values obtained between 21 days before inclusion andrandomization, respecting the following criteria:
* Absolute neutrophil count (ANC) ≥1500 /mm3
* Platelet count ≥100,000 / mm3
* Hemoglobin \> 9.0 g/dL
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN)
* SGOT (AST) ≤ 3 x ULN
* Negative serum or urine pregnancy test done ≤ 7 days prior to registration, for women of childbearing potential only.
* Provide informed written consent

Exclusion Criteria:

* Pregnant and nursing women
* Men or women of childbearing potential who are unwilling to employ adequate contraception for up to 6 months following the completion of PCV.
* Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
* Co-morbid systemic illnesses or other severe concurrent disease which would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
* Concomitant serious immunocompromised status (other than that related to concomitant steroids).
* Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements.
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm (except specific inhibitors of IDH)
* Other active malignancy within 5 years of registration. Exceptions: Non-melanotic skin cancer or carcinoma-in-situ of the cervix.
* Contra-indication to CCNU: hypersensitivity to CCNU, wheat allergy, association to yellow fever vaccin
* Contra-indication to Procarbazine: severe renal failure, severe hepatic failure, hypersensitivity to procarbazine, association to yellow fever vaccin
* Contra-indication to Vincristine: hypersensitivity to vincristine, neuromuscular disorder (for example demyelinating Charcot-Mary Tooth neuropathy), severe renal failure, severe hepatic failure.
* Not depending from the french system of health assurance

Where it's running

• CHU d'Amiens-Picardie Site Sud
  Amiens, France Recruiting
• Institut de Cancerologie de l'Ouest
  Angers, France Recruiting
• CHU de Bordeaux Hôpital Saint André
  Bordeaux, France Recruiting
• Institut de Cancérologie et Hematologie (ICH) - CHRU Brest, Hopital Morvan
  Brest, France Recruiting
• Hospices Civils de Lyon
  Bron, France Recruiting
• Hôpital Roger Salengro CHU de Lille
  Lille, France Recruiting

Study contacts

• Study coordinator: François DUCRAY, MD, PhD
• Email: francois.ducray@chu-lyon.fr
• Phone: +33(0) 4 72 35 78 06

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Safusidenib in IDH1-mutant glioma after vorasidenib progression

  This trial tests safusidenib in people with IDH1-mutant glioma who progressed on vorasidenib and did not need immediate chemo or radiation.

  Recruiting at 2 sites Phase 2 Nuvation Bio Inc. · Los Angeles, California and 11 other locations · NCT07703436

• Pre-radiation chemotherapy for high-grade glioma

  Researchers are testing whether giving temozolomide before radiation can help patients with newly diagnosed high-grade gliomas see better outcomes and clearer MRI results after treatment.

  Recruiting Phase 2 Cooper Norcross Health · Camden, New Jersey · NCT07439172

• FearLess for adults with malignant brain tumors and their caregivers

  This project will test whether the FearLess psychological program can reduce fear of cancer recurrence in adults with primary malignant brain tumors and their nonprofessional caregivers.

  Recruiting Virginia Commonwealth University · Richmond, Virginia · NCT06989086

• Home-based self-management and cognitive training for brain tumor survivors

  This trial will try a home-based cognitive coaching program to see if it improves thinking and quality of life for adults who survived non-glioblastoma brain tumors, with optional caregiver participation.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT06930846

• Treatment of high-grade glioma in young patients using olutasidenib and temozolomide

  This study is testing if a new combination of olutasidenib and temozolomide can help young patients with high-grade gliomas that have a specific mutation feel better after their radiotherapy.

  Recruiting at 8 sites Phase 2 Rigel Pharmaceuticals · Aurora, Colorado and 19 other locations · NCT06161974

• Treatment for young patients with relapsed or refractory brain tumors

  This study is testing a new way to deliver cancer drugs directly to the brain tumors of young patients under 22 who have not responded to other treatments, to see if it helps them feel better.

  Recruiting Phase 1/2 University of Miami · Miami, Florida · NCT05956821

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.